Company Initiates Search for New Chief Executive Officer MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive management team. David Gill, a current Melinta...
Author: @admin
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
Company Initiates Search for New Chief Executive Officer MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive management team. David Gill, a current Melinta...
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
~ Revenue of$16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3 million, Year-Over-Year ~ ~ Commenced Enrollment in Clinical Trial Evaluating Orbactiv® (oritavancin) Shorter Infusion Time Formulation in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ~...
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and six months ended June 30, 2019 and recent corporate highlights. “Nabriva has made significant advances in the second...
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
JERSEY CITY, N.J., Aug. 7, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended June 30, 2019, and provided an update on recent clinical developments. “We are pleased with the rapid enrollment observed in our Phase 3 VANISH program...
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting
~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~ ~ Company Cancels Previously Scheduled Earnings Call ~ MORRISTOWN, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced...
Nabriva Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Chief Commercial Officer Francesco Maria Lavino will provide a company overview and business update at the 2019 Wedbush PacGrow...
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
DUBLIN, Ireland and CHICAGO, Aug. 01, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced its participation at the Canaccord Genuity...
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Oxford, UK, and Cambridge, MA, US, 1 August 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity...
SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
JERSEY CITY, N.J., July 31, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August 7, 2019 at 5:00 p.m. ET. A live webcast...